Strategy& Insider

Strategy& Insider

Exploring future trends and their impacts

Strategy& Insider Episode 48 - Rewriting medicine with CRISPR and genome editing

Download it: MP3 | AAC | OGG | OPUS
Read transcript

What if curing a disease took a single treatment instead of a lifetime of pills, and the same technology could help cool the planet? In this episode, Dr. Bradley Ringeisen, Executive Director of the Innovative Genomics Institute (IGI) at UC Berkeley, takes us inside the CRISPR revolution. From the first FDA-approved sickle cell therapy to a custom cure that saved a baby's life in Philadelphia, to rice engineered to emit 60% less methane, Brad reveals how genome editing is reshaping medicine, climate, and food security alike. We dig into the science, the make-or-break "delivery" challenge, and the IGI's "CRISPR Commons" initiative, a bold plan to make genome editing equitably accessible worldwide.


Comments


New comment

Your name or nickname, will be shown publicly
At least 10 characters long
By submitting your comment you agree that the content of the field "Name or nickname" will be stored and shown publicly next to your comment. Using your real name is optional.

About this podcast

The Strategy& Insider podcast aims to explore some of the most critical future trends and their impacts. Strategy& talks to industry experts and leading practitioners from different sectors. The conversations will make you more familiar with key developments by providing you with insights that really matter.

The first season will tackle some of the most fundamental questions in the healthcare industry. While technology has quickly transformed how we shop, bank, and travel, it yet has to impact on how we receive healthcare. The adoption of digitally enabled tools for diagnostics, treatment, and management, for example, has been rather modest - especially compared to what is already possible.

Together with experts across all sectors including pharma executives, leading academics and practitioners at hospitals we will discuss how the healthcare industry is expected to change.

by Thomas Solbach, Ghioia Irritier, Jan-Philipp Loch

Subscribe

Follow us